CLINICAL NEWS
Early Discharge Versus Inpatient Care for AML
or MDS Patients
For patients with acute myeloid leukemia (AML) or myelodysplastic syndromes
(MDS), induction therapy often requires patients to remain hospitalized until blood cell
count recovery, typically resulting in prolonged hospitalization
stays, increased health resource
use, and increased costs. According to results from a study
published in JAMA Oncology,
outpatient management of these
patients is a cost-effective approach – cutting daily costs by
more than $2,000 – but early
discharge carries with it a higher
risk for certain complications.
Outpatient
management
of AML and
MDS patients
cuts daily
costs but carries a higher
risk for certain
complications.
follow-up, securing a reliable caregiver, and
residency within 60 minutes of the outpatient clinic) were selected for the outpatient
management cohort. Twenty-nine patients
who met the medical criteria but not the
logistic criteria, served as inpatient controls.
Patients remained on protocol until
blood count recovery, additional chemo-
LET HIM EXPLORE
A NATURAL PATHWAY
ELOCTATE, the first and only rFVIII
that uses Fc fusion to prolong half-life
Selected Important Safety Information
• ELOCTATE is contraindicated in patients who have had
life-threatening hypersensitivity reactions to ELOCTATE,
including anaphylaxis
Please see below for additional Important Safety
Information and see full Brief Summary on the next page.
GET TO KNOW ELOCTATE
Fc FUSION
ELOCTATE offers a prolonged
half-life using one of the body’s
NATURAL PATHWAYS1,2
Jennifer E. Vaughn, MD,
from Fred Hutchinson Cancer
Research Center in Seattle,
Washington, and colleagues conducted a nonrandomized, phase
II, single-center study at the
University of Washington Medical Center to compare the safety,
resource use, infections, and
costs associated with inpatient
versus outpatient chemotherapy
in AML and MDS patients.
From January 1, 2011,
through July 31, 2014, the investigators enrolled 136 patients
who received induction chemotherapy into the study. Those
who met the designated medical
and logistic criteria for early
discharge following completion
of induction chemotherapy (including ECOG performance status of 0-1 with adequate organ
function and no active bleeding,
agreeable to close outpatient
Routine prophylaxis
starting dosing interval of
EVERY
4
DAYS*
*Recommended prophylaxis starting dose of 50 IU/kg every 4 days, with adjustments based on patient response in the range of 25-65 IU/kg at 3- to 5-day intervals.
More frequent or higher doses up to 80 IU/kg may be required in children <6 years of age. The one-stage clotting assay or chromogenic assay can be used to
monitor plasma FVIII levels after administering ELOCTATE.
rFVIII=recombinant Factor VIII.
Indications and Important Safety Information
INDICATIONS: ELOCTATE [Antihemophilic Factor (Recombinant),
Fc Fusion Protein] is a recombinant DNA derived, antihemophilic
factor indicated in adults and children with Hemophilia A
(congenital Factor VIII deficiency) for: control and prevention
of bleeding episodes, perioperative management (surgical
prophylaxis), and routine prophylaxis to prevent or reduce
the frequenc